Reverse Micellar Radioprotector System for Radiation Injury

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current radiation countermeasures lack effectiveness in treating and preventing radiation injuries due to limitations such as short-time windows, high toxicity, and difficulty in administration, especially in mass-casualty situations, and existing reverse micelle systems are not adapted for radiation damage treatment.

Innovation Solution

A reverse micellar system comprising 50-90% acylglycerol, 1-20% lecithin, ethanol, and water, optionally with an active agent like manganese, is administered to treat and prevent radiation damage, offering a stable, easy-to-handle, and wide-window protection solution.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If amifostine is administered intravenously or subcutaneously, then radioprotection efficacy is improved, but ease of operation deteriorates and time window for effectiveness is reduced

Engineering Contradiction:

Improveradioprotection efficacyVSAvoidease of administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physical-chemical parameters of the radioprotector by formulating it in a reverse micellar system with specific composition ratios (acylglycerol 50-90%, lecithin 1-20%, ethanol, and water). This formulation transformation enables the drug to be administered orally while maintaining radioprotection efficacy, thus improving ease of operation without sacrificing reliability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The reverse micellar system acts as an intermediary carrier that facilitates the delivery of the radioprotector (amifostine or other compounds) to the target tissues. The micellar structure with its specific hydrophobic and hydrophilic components mediates between the drug and the biological system, enabling effective oral absorption and distribution while extending the time window of effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If amifostine is administered, then radioprotection is improved, but loss of time increases due to short-time window of effectiveness

Engineering Contradiction:

ImproveradioprotectionVSAvoidtime window of effectiveness

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The reverse micellar formulation enables continuous radioprotection by maintaining stable drug release and sustained therapeutic levels in the body. The unique micellar structure provides continuous protection over an extended time window, eliminating the need for frequent re-administration and ensuring uninterrupted radioprotection efficacy

Inventive Principle:

Principle #20Continuity of useful action

3Reliability

If manganese is administered to enhance SOD activity, then radioprotection is improved, but object-generated harmful factors increase due to toxicity and neurodegenerative damage

Engineering Contradiction:

ImproveradioprotectionVSAvoidtoxicity and neurodegenerative damage

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the delivery parameters of manganese by incorporating it into the reverse micellar system at controlled concentrations (0.1-10 mM). This controlled delivery system releases manganese gradually, maintaining effective levels for SOD activation while preventing toxic accumulation in tissues, thus resolving the contradiction between radioprotection efficacy and toxicity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The reverse micellar system serves as an intermediary that safely transports manganese to target tissues. The micellar structure controls the release and distribution of manganese, acting as a protective carrier that enables therapeutic effects while minimizing direct contact between free manganese ions and sensitive tissues, thereby reducing neurodegenerative damage

Inventive Principle:

Principle #24Intermediary (Mediator)

4Ease of operation

If existing reverse micelle systems are used, then ease of operation is improved, but applicability to radiation damage treatment deteriorates

Engineering Contradiction:

Improveeasy to handleVSAvoidadaptability to radiation damage treatment

Core Design Contradiction:

Ease of operationVSAdaptability or versatility

Solution Approach 1:

The patent creates a universal reverse micellar system with a balanced composition (acylglycerol 50-90%, lecithin 1-20%, ethanol, and water) that can accommodate multiple radioprotectors including amifostine, manganese, and other compounds. This multi-functional formulation maintains ease of handling while being specifically adapted for radiation damage treatment through its ability to deliver different active agents effectively

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The reverse micellar system effectively increases survival rates in irradiated mice by reducing radiation-induced damage, with manganese formulations showing improved efficacy at higher doses and varied administration schedules, suggesting potential as a medical countermeasure for severe radiation injuries.

Implementation Method 1

Superoxide dismutases (SOD) are enzymes that catalyze the dismutation of superoxide anions to oxygen and hydrogen peroxide and they are known for the involvement in antioxidant defense mechanisms

Methodology Applied

Scientific EffectAntioxidant defense mechanism: Oxidation

Data Source

PatentUS11793831B2Treatment and prevention of injury due to radiation exposure

Publication Date: 2023.10.24 MEDESIS PHARMA SA

AI summary

The disclosure relates to the treatment and/or prevention of radiation damage by administering a reverse micelle system.